Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

被引：0

作者：

Hauser, Stephen ^{[1
]}

Li, David ^{[2
]}

Calabresi, Peter ^{[3
]}

O'Connor, Paul ^{[4
]}

Bar-Or, Amit ^{[5
,6
]}

Barkhof, Frederik ^{[7
]}

Sauter, Annette ^{[8
]}

Leppert, David ^{[9
]}

Masterman, Donna ^{[8
]}

Tinbergen, Jeroen ^{[8
]}

Kappos, Ludwig ^{[10
,11
]}

机构：

[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[3] Johns Hopkins Univ, Baltimore, MD USA

[4] Univ Toronto, Dept Neurol, Toronto, ON, Canada

[5] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada

[6] McGill Univ, Montreal Neurol Inst & Hosp, Expt Therapeut Program, Montreal, PQ, Canada

[7] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands

[8] F Hoffmann La Roche Ltd, Basel, Switzerland

[9] PDCN F Hoffmann La Roche, Basel, Switzerland

[10] Univ Basel Hosp, CH-4031 Basel, Switzerland

[11] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S31004

引用

页数：2

共 50 条

[1] Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial
Hauser, Stephen
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Wells, Chris
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
NEUROLOGY, 2012, 78
[2] Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Yin, Ming
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
Hauser, Stephen
NEUROLOGY, 2011, 76 (09) : A545 - A545
[3] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Wells, C.
Leppert, D.
Masterman, D.
Tinbergen, J.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 140 - 141
[4] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: Week 144 results of a Phase II, randomised, multicentre trial
Kappos, L.
Bar-Or, A.
Sauter, A.
Leppert, D.
Li, D.
Masterman, D.
Barkhof, F.
Tinbergen, J.
O'Connor, P.
Calabresi, P. A.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1875 - 1875
[5] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzmann, R.
Tinbergen, J.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S194 - S195
[6] Ocrelizumab in relapsing-remitting multiple sclerosis: 72-week efficacy and safety results of a phase II, randomised, placebo-controlled, multi-centre trial
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzman, R.
Tinbergen, J.
Hauser, S.
JOURNAL OF NEUROLOGY, 2011, 258 : 14 - 14
[7] Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Wells, C.
Leppert, D.
Glanzman, R.
Tinbergen, J.
Hauser, S.
JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S65
[8] A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS)
Hauser, Stephen
Waubant, Emmanuelle
Arnold, Douglas
Vollmer, Timothy
Antel, Jack
Fox, Robert
Bar-Or, Amit
Sarkar, Neena
Langer-Gould, Annette
Panzara, Michael
Smith, Craig
NEUROLOGY, 2007, 68 (12) : A99 - A100
[9] A phase 1, open-label, multicenter study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS): 72 week results
Bar-Or, Amit
Calabresi, Peter
Arnold, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd
Waubant, Emmanuelle
Gazda, Suzanne
Fox, Robert
Sarkar, Neena
Panzara, Michael
Smith, Craig
NEUROLOGY, 2008, 70 (11) : A119 - A120
[10] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Doshi, Anisha
Voysey, Zanna
Bunting, Eva
Malik, Muzaffar
Rashid, Waqar
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):

← 1 2 3 4 5 →